NFE2L2 and cancer: Furthermore, the possibility of exacerbating cardiomyopathy with Nrf2 exogenous modulation and concerns over chemotherapy resistance from Nrf2-mediated antioxidant enzymes upregulated in cancer cells make the use of such compounds questionable for clinical applications [47].